In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.